{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:05:45Z","timestamp":1786561545964,"version":"build-2736575974"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000867","name":"Commonwealth Scholarship Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Incidence of pulmonary aspergillosis is rising worldwide, owing to an increased population of immunocompromised patients. Notable potential of the pulmonary route has been witnessed in antifungal delivery due to distinct advantages of direct lung targeting and first-pass evasion. The current research reports biomimetic surface-active lipid-polymer hybrid (LPH) nanoparticles (NPs) of voriconazole, employing lung-specific lipid, <jats:italic>i.e.<\/jats:italic>, dipalmitoylphosphatidylcholine and natural biodegradable polymer, <jats:italic>i.e.,<\/jats:italic> chitosan, to augment its pulmonary deposition and retention, following nebulization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The developed nanosystem exhibited a particle size in the range of 228\u2013255\u00a0nm and drug entrapment of 45\u201354.8%. Nebulized microdroplet characterization of NPs dispersion revealed a mean diameter of \u2009\u2264\u20095\u00a0\u03bcm, corroborating its deep lung deposition potential as determined by next-generation impactor studies. Biophysical interaction of LPH NPs with lipid-monolayers indicated their surface-active potential and ease of intercalation into the pulmonary surfactant membrane at the air-lung interface. Cellular viability and uptake studies demonstrated their cytocompatibility and time-and concentration-dependent uptake in lung-epithelial A549 and Calu-3 cells with clathrin-mediated internalization. Transepithelial electrical resistance experiments established their ability to penetrate tight airway Calu-3 monolayers. Antifungal studies on laboratory strains and clinical isolates depicted their superior efficacy against Aspergillus species. Pharmacokinetic studies revealed nearly 5-, 4- and threefolds enhancement in lung AUC, T<jats:sub>max<\/jats:sub>, and MRT values, construing significant drug access and retention in lungs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Nebulized LPH NPs were observed as a promising solution to provide effective and safe therapy for the management of pulmonary aspergillosis infection with improved patient compliance and avoidance of systemic side-effects. <\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12951-020-00731-1","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T12:19:19Z","timestamp":1610367559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention"],"prefix":"10.1186","volume":"19","author":[{"given":"Ranjot","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Burrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaprakash M.","family":"Rudramurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Swami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Gorki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. P.","family":"Katare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7325-0711","authenticated-orcid":false,"given":"Kamalinder K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"731_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jhin.2019.09.020","volume":"104","author":"RW Dib","year":"2020","unstructured":"Dib RW, Khalil M, Fares J, Hachem RY, Jiang Y, Dandachi D, Chaftari AM, Raad II. Invasive pulmonary aspergillosis: comparative analysis in cancer patients with underlying haematologic malignancies versus solid tumours. J Hosp Infect. 2020;104:358\u201364.","journal-title":"J Hosp Infect"},{"key":"731_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-018-0611-y","volume":"18","author":"X Tong","year":"2018","unstructured":"Tong X, Cheng A, Xu H, Jin J, Yang Y, Zhu S, Li Y. Aspergillus fumigatus during COPD exacerbation: a pair-matched retrospective study. BMC Pulm Med. 2018;18:1\u20138.","journal-title":"BMC Pulm Med"},{"key":"731_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13613-020-00686-4","volume":"10","author":"L Rutsaert","year":"2020","unstructured":"Rutsaert L, Steinfort N, Van Hunsel T, Bomans P, Naesens R, Mertes H, Dits H, Van Regenmortel N. COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care. 2020;10:1\u20134.","journal-title":"Ann Intensive Care"},{"key":"731_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/myc.13096","volume":"63","author":"P Koehler","year":"2020","unstructured":"Koehler P, Cornely OA, B\u00f6ttiger BW, Dusse F, Eichenauer DA, Fuchs F, Hallek M, Jung N, Klein F, Persigehl T. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63:528\u201334.","journal-title":"Mycoses"},{"key":"731_CR5","doi-asserted-by":"crossref","unstructured":"Alanio A, Delli\u00e8re S, Fodil S, Bretagne S, M\u00e9garbane B: Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med 2020.","DOI":"10.1101\/2020.04.21.20064915"},{"key":"731_CR6","doi-asserted-by":"crossref","unstructured":"Prattes J, Valentin T, Hoenigl M, Talakic E, Reisinger AC, Eller P: Invasive pulmonary aspergillosis complicating COVID-19 in the ICU-A case report. Med Mycol Case Rep 2020.","DOI":"10.1016\/j.mmcr.2020.05.001"},{"key":"731_CR7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","volume":"6","author":"AFAD Schauwvlieghe","year":"2018","unstructured":"Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, Lagrou K, Verweij PE, Van de Veerdonk FL, Gommers D. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6:782\u201392.","journal-title":"Lancet Respir Med"},{"key":"731_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018025781","volume":"36","author":"R Kaur","year":"2019","unstructured":"Kaur R, Kaur R, Singh C, Kaur S, Goyal AK, Singh KK, Singh B. Inhalational drug delivery in pulmonary aspergillosis. Crit Rev Ther Drug Carrier Syst. 2019;36:183\u2013217.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"731_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4103\/0970-2113.92361","volume":"29","author":"JS Patil","year":"2012","unstructured":"Patil JS, Sarasija S. Pulmonary drug delivery strategies: a concise, systematic review. Lung India. 2012;29:44\u20139.","journal-title":"Lung India"},{"key":"731_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1178636119869937","volume":"12","author":"MJ Duckwall","year":"2019","unstructured":"Duckwall MJ, Gales MA, Gales BJ. Inhaled amphotericin B as aspergillosis prophylaxis in hematologic disease: an update. Microbiol Insights. 2019;12:1\u20137.","journal-title":"Microbiol Insights"},{"key":"731_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/MD.0b013e3181e9441b","volume":"89","author":"A Safdar","year":"2010","unstructured":"Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN, Chandrasekar PH, Kontoyiannis DP, Rolston KV. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine. 2010;89:236\u201344.","journal-title":"Medicine"},{"key":"731_CR12","doi-asserted-by":"crossref","unstructured":"Le J., Ashley ED, Neuhauser MM, Brown J, Gentry C, Klepser ME, Marr AM, Schiller D, Schwiesow JN, Tice S, et al: Consensus summary of aerosolized antimicrobial agents: Application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2010, 30:562-584.","DOI":"10.1592\/phco.30.6.562"},{"key":"731_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ijantimicag.2016.11.007","volume":"49","author":"Y Yu","year":"2017","unstructured":"Yu Y, Zhu C, Liu C, Gao Y. Amphotericin B nebulisation for invasive pulmonary aspergillosis prophylaxis: the conflict of ideality and reality. Int J Antimicrob Agents. 2017;49:263.","journal-title":"Int J Antimicrob Agents"},{"key":"731_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408\u201315.","journal-title":"N Engl J Med"},{"key":"731_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/2050-6511-15-52","volume":"15","author":"H Ostermann","year":"2014","unstructured":"Ostermann H, Solano C, Jarque I, Garcia-Vidal C, Gao X, Barrueta JA, De Salas-Cansado M, Stephens J, Xue M, Weber B. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. BMC Pharmacol Toxicol. 2014;15:52.","journal-title":"BMC Pharmacol Toxicol"},{"key":"731_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5339\/gcsp.2015.2","volume":"2015","author":"IM El-Sherbiny","year":"2015","unstructured":"El-Sherbiny IM, El-Baz NM, Yacoub MH. Inhaled nano-and microparticles for drug delivery. Glob Cardiol Sci Pract. 2015;2015:2\u201314.","journal-title":"Glob Cardiol Sci Pract"},{"key":"731_CR17","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1021\/acs.biomac.5b01480","volume":"17","author":"EF Craparo","year":"2016","unstructured":"Craparo EF, Porsio BM, Sardo C, Giammona G, Cavallaro G. Pegylated polyaspartamide\u2013polylactide-based nanoparticles penetrating cystic fibrosis artificial mucus. Biomacromol. 2016;17:767\u201377.","journal-title":"Biomacromol"},{"key":"731_CR18","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1021\/bm401122q","volume":"14","author":"T Yin","year":"2013","unstructured":"Yin T, Bader A, Hou TK, Maron BA, Kao DD, Qian R, Kohane DS, Handy DE, Loscalzo J, Zhang YY. SDF-1\u03b1 in glycan nanoparticles exhibits full activity and reduces pulmonary hypertension in rats. Biomacromol. 2013;14:4009\u201320.","journal-title":"Biomacromol"},{"key":"731_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF, Campos EVR, del Pilar Rodriguez-Torres M, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16:71.","journal-title":"J Nanobiotechnology"},{"key":"731_CR20","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1021\/bm201226x","volume":"12","author":"S Mura","year":"2011","unstructured":"Mura S, Hillaireau H, Nicolas J, Kerdine-R\u00f6mer S, Le Droumaguet B, Delom\u00e9nie C, Nicolas V, Pallardy M, Tsapis N, Fattal E. Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells. Biomacromol. 2011;12:4136\u201343.","journal-title":"Biomacromol"},{"key":"731_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jconrel.2015.03.015","volume":"206","author":"L De Backer","year":"2015","unstructured":"De Backer L, Braeckmans K, Stuart MC, Demeester J, De Smedt SC, Raemdonck K. Bio-inspired pulmonary surfactant-modified nanogels: a promising siRNA delivery system. J Control Release. 2015;206:177\u201386.","journal-title":"J Control Release"},{"key":"731_CR22","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.1038\/srep07085","volume":"4","author":"N Joshi","year":"2014","unstructured":"Joshi N, Shirsath N, Singh A, Joshi KS, Banerjee R. Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases. Sci Rep. 2014;4:7085.","journal-title":"Sci Rep"},{"key":"731_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejpb.2019.09.020","volume":"144","author":"C Garcia-Mouton","year":"2019","unstructured":"Garcia-Mouton C, Hidalgo A, Cruz A, P\u00e9rez-Gil J. The Lord of the Lungs: the essential role of pulmonary surfactant upon inhalation of nanoparticles. Eur J Pharm Biopharm. 2019;144:230\u201343.","journal-title":"Eur J Pharm Biopharm"},{"key":"731_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1477-3155-8-31","volume":"8","author":"M Gasser","year":"2010","unstructured":"Gasser M, Rothen-Rutishauser B, Krug HF, Gehr P, Nelle M, Yan B, Wick P. The adsorption of biomolecules to multi-walled carbon nanotubes is influenced by both pulmonary surfactant lipids and surface chemistry. J Nanobiotechnol. 2010;8:31.","journal-title":"J Nanobiotechnol"},{"key":"731_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1773-2247(10)50004-2","volume":"20","author":"A Grenha","year":"2010","unstructured":"Grenha A, Al-Qadi S, Seijo B, Remu\u00f1\u00e1n-L\u00f3pez C. The potential of chitosan for pulmonary drug delivery. J Drug Deliv Sci Technol. 2010;20:33\u201343.","journal-title":"J Drug Deliv Sci Technol"},{"key":"731_CR26","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1021\/bm5008635","volume":"15","author":"MDA Muhsin","year":"2014","unstructured":"Muhsin MDA, George G, Beagley K, Ferro V, Armitage C, Islam N. Synthesis and toxicological evaluation of a chitosan-l-leucine conjugate for pulmonary drug delivery applications. Biomacromol. 2014;15:3596\u2013607.","journal-title":"Biomacromol"},{"key":"731_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-019-0529-4","volume":"17","author":"S Niu","year":"2019","unstructured":"Niu S, Williams GR, Wu J, Wu J, Zhang X, Chen X, Li S, Jiao J, Zhu LM. A chitosan-based cascade-responsive drug delivery system for triple-negative breast cancer therapy. J Nanobiotechnol. 2019;17:1\u201318.","journal-title":"J Nanobiotechnol"},{"key":"731_CR28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/pat.1306","volume":"20","author":"H Liu","year":"2009","unstructured":"Liu H, Gao C. Preparation and properties of ionically crosslinked chitosan nanoparticles. Polym Adv Technol. 2009;20:613\u20139.","journal-title":"Polym Adv Technol"},{"key":"731_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v22.i1.20","volume":"22","author":"B Singh","year":"2005","unstructured":"Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic \u201cdesign of experiments. Part I: Fundamental aspects. Crit Rev Ther Drug Carrier Syst. 2005;22:27\u2013105.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"731_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejpb.2017.09.001","volume":"121","author":"RK Khurana","year":"2017","unstructured":"Khurana RK, Beg S, Burrow AJ, Vashishta RK, Katare OP, Kaur S, Kesharwani P, Singh KK, Singh B. Enhancing biopharmaceutical performance of an anticancer drug by long chain PUFA based self-nanoemulsifying lipidic nanomicellar systems. Eur J Pharm Biopharm. 2017;121:42\u201360.","journal-title":"Eur J Pharm Biopharm"},{"key":"731_CR31","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/10717544.2019.1642420","volume":"26","author":"MM Khan","year":"2019","unstructured":"Khan MM, Madni A, Torchilin V, Filipczak N, Pan J, Tahir N, Shah H. Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin. Drug Deliv. 2019;26:765\u201372.","journal-title":"Drug Deliv"},{"key":"731_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/chromsci\/45.7.409","volume":"45","author":"J He","year":"2007","unstructured":"He J, Cheng S, Qiu F, Huang J. Development and validation of a simple and rapid HPLC method for the quantitative determination of voriconazole in rat and beagle dog plasma. J Chromatogr Sci. 2007;45:409\u201314.","journal-title":"J Chromatogr Sci"},{"key":"731_CR33","doi-asserted-by":"publisher","first-page":"113734","DOI":"10.1016\/j.molliq.2020.113734","volume":"316","author":"C Houacine","year":"2020","unstructured":"Houacine C, Adams D, Singh KK. Impact of liquid lipid on development and stability of trimyristin nanostructured lipid carriers for oral delivery of resveratrol. J Mol Liq. 2020;316:113734.","journal-title":"J Mol Liq"},{"key":"731_CR34","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1021\/mp500808t","volume":"12","author":"S Arora","year":"2015","unstructured":"Arora S, Haghi M, Loo CY, Traini D, Young PM, Jain S. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection. Mol Pharm. 2015;12:2001\u20139.","journal-title":"Mol Pharm"},{"key":"731_CR35","doi-asserted-by":"publisher","first-page":"38030","DOI":"10.1039\/C5RA00248F","volume":"5","author":"S Arora","year":"2015","unstructured":"Arora S, Mahajan RR, Kushwah V, Baradia D, Misra A, Jain S. Development of voriconazole loaded large porous particles for inhalation delivery: effect of surface forces on aerosolisation performance, assessment of in vitro safety potential and uptake by macrophages. RSC Adv. 2015;5:38030\u201343.","journal-title":"RSC Adv"},{"key":"731_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejpb.2006.07.007","volume":"65","author":"N Ahuja","year":"2007","unstructured":"Ahuja N, Katare OP, Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur J Pharm Biopharm. 2007;65:26\u201338.","journal-title":"Eur J Pharm Biopharm"},{"key":"731_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/jps.10558","volume":"93","author":"A Haynes","year":"2004","unstructured":"Haynes A, Shaik MS, Krarup H, Singh M. Evaluation of the Malvern Spraytec\u00ae with inhalation cell for the measurement of particle size distribution from metered dose inhalers. J Pharm Sci. 2004;93:349\u201363.","journal-title":"J Pharm Sci"},{"key":"731_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/jamp.2012.1030","volume":"27","author":"N Lelong","year":"2014","unstructured":"Lelong N, Junqua-Moullet A, Diot P, Vecellio L. Comparison of laser diffraction measurements by Mastersizer X and Spraytec to characterize droplet size distribution of medical liquid aerosols. J Aerosol Med Pulm Drug Deliv. 2014;27:94\u2013102.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"731_CR39","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1208\/s12249-015-0346-5","volume":"17","author":"X Song","year":"2016","unstructured":"Song X, Hu J, Zhan S, Zhang R, Tan W. Effects of temperature and humidity on laser diffraction measurements to jet nebulizer and comparison with NGI. AAPS PharmSciTech. 2016;17:380\u20138.","journal-title":"AAPS PharmSciTech"},{"key":"731_CR40","unstructured":"MMAD Calculator. http:\/\/www.mmadcalculator.com. (Accessed 13 April 2020)."},{"key":"731_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/jamp.2008.0650","volume":"22","author":"ME Abdelrahim","year":"2009","unstructured":"Abdelrahim ME, Chrystyn H. Aerodynamic characteristics of nebulized terbutaline sulphate using the Next Generation Impactor (NGI) and CEN method. J Aerosol Med Pulm Drug Deliv. 2009;22:19\u201328.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"731_CR42","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/jamp.2011-0966","volume":"26","author":"G Mainelis","year":"2013","unstructured":"Mainelis G, Seshadri S, Garbuzenko OB, Han T, Wang Z, Minko T. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice. J Aerosol Med Pulm Drug Deliv. 2013;26:345\u201354.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"731_CR43","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1039\/c2sm07147a","volume":"8","author":"SR Dennison","year":"2012","unstructured":"Dennison SR, Akbar Z, Phoenix DA, Snape TJ. Interactions between suitably functionalised conformationally distinct benzanilides and phospholipid monolayers. Soft Matter. 2012;8:3258\u201364.","journal-title":"Soft Matter"},{"key":"731_CR44","first-page":"e1963","volume":"6","author":"A Bittame","year":"2015","unstructured":"Bittame A, Lopez J, Effantin G, Blanchard N, Cesbron-Delauw MF, Gagnon J, Mercier C. Lipid extraction from HeLa cells, quantification of lipids, formation of large unilamellar vesicles (LUVs) by extrusion and in vitro protein-lipid binding assays, analysis of the incubation product by Transmission Electron Microscopy (TEM) and by flotation across a discontinuous sucrose gradient. Bio Protoc. 2015;6:e1963.","journal-title":"Bio Protoc"},{"key":"731_CR45","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/0005-2736(87)90400-7","volume":"899","author":"A Seelig","year":"1987","unstructured":"Seelig A. Local anesthetics and pressure: a comparison of dibucaine binding to lipid monolayers and bilayers. Biochim Biophys Acta. 1987;899:196\u2013204.","journal-title":"Biochim Biophys Acta"},{"key":"731_CR46","unstructured":"CLSI: Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-3rd edition. In CLSI document M 27-A3 Wayne, PA: Clinical and Laboraotry Standard Institute 2008."},{"key":"731_CR47","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.msec.2018.05.010","volume":"91","author":"RK Khurana","year":"2018","unstructured":"Khurana RK, Kumar R, Gaspar BL, Welsby G, Welsby P, Kesharwani P, Katare OP, Singh KK, Singh B. Clathrin-mediated endocytic uptake of PUFA enriched self-nanoemulsifying lipidic systems (SNELS) of an anticancer drug against triple negative cancer and DMBA induced preclinical tumor model. Mater Sci Eng C. 2018;91:645\u201358.","journal-title":"Mater Sci Eng C"},{"key":"731_CR48","doi-asserted-by":"crossref","unstructured":"Harcourt JL, Haynes LM: Establishing a liquid-covered culture of polarized human airway epithelial Calu-3 cells to study host cell response to respiratory pathogens in vitro. JoVE 2013:e50157.","DOI":"10.3791\/50157-v"},{"key":"731_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1046\/j.1365-2125.2003.01994.x","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol. 2003;56:17\u201323.","journal-title":"Br J Clin Pharmacol"},{"key":"731_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijpharm.2009.06.003","volume":"379","author":"JA Tolman","year":"2009","unstructured":"Tolman JA, Nelson NA, Bosselmann S, Peters JI, Coalson JJ, Wiederhold NP, Williams RO III. Dose tolerability of chronically inhaled voriconazole solution in rodents. Int J Pharm. 2009;379:25\u201331.","journal-title":"Int J Pharm"},{"key":"731_CR51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.21037\/atm.2019.09.44","volume":"7","author":"EM Chinese","year":"2019","unstructured":"Chinese EM. Expert consensus on nebulization therapy in pre-hospital and in-hospital emergency care. Ann Transl Med. 2019;7:487.","journal-title":"Ann Transl Med"},{"key":"731_CR52","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1517\/17425247.2016.1114603","volume":"13","author":"S Arora","year":"2016","unstructured":"Arora S, Haghi M, Young PM, Kappl M, Traini D, Jain S. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability. Expert Opin Drug Deliv. 2016;13:183\u201393.","journal-title":"Expert Opin Drug Deliv"},{"key":"731_CR53","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99:306\u201314.","journal-title":"Comput Methods Programs Biomed"},{"key":"731_CR54","first-page":"3","volume-title":"ICHQ1A (R2) stability testing of new drug substance and product and ICHQ1C stability testing of new dosage forms","author":"A Rignall","year":"2017","unstructured":"Rignall A. ICHQ1A (R2) stability testing of new drug substance and product and ICHQ1C stability testing of new dosage forms. ICH Quality Guidelines: An Implementation Guide; 2017. p. 3."},{"key":"731_CR55","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ijpharm.2017.11.045","volume":"535","author":"E Baghdan","year":"2018","unstructured":"Baghdan E, Pinnapireddy SR, Strehlow B, Engelhardt KH, Schafer J, Bakowsky U. Lipid coated chitosan-DNA nanoparticles for enhanced gene delivery. Int J Pharm. 2018;535:473\u20139.","journal-title":"Int J Pharm"},{"key":"731_CR56","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1166\/jnn.2008.18140","volume":"8","author":"A Grenha","year":"2008","unstructured":"Grenha A, Seijo B, Serra C, Remu\u00f1\u00e1n-L\u00f3pez C. Surface characterization of lipid\/chitosan nanoparticles assemblies, using X-Ray photoelectron spectroscopy and time-of-flight secondary ion mass spectrometry. J Nanosci Nanotechnol. 2008;8:358\u201365.","journal-title":"J Nanosci Nanotechnol"},{"key":"731_CR57","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.nano.2012.04.005","volume":"9","author":"B Sinha","year":"2013","unstructured":"Sinha B, Mukherjee B, Pattnaik G. Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: in vitro and in vivo study. Nanomedicine. 2013;9:94\u2013104.","journal-title":"Nanomedicine"},{"key":"731_CR58","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jpba.2016.09.047","volume":"132","author":"P F\u00fcredi","year":"2017","unstructured":"F\u00fcredi P, P\u00e1pay ZE, Kov\u00e1cs K, Kiss BD, Lud\u00e1nyi K, Antal I, Klebovich I. Development and characterization of the voriconazole loaded lipid-based nanoparticles. J Pharm Biomed Anal. 2017;132:184\u20139.","journal-title":"J Pharm Biomed Anal"},{"key":"731_CR59","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbamem.2012.10.013","volume":"1828","author":"B Pawlikowska-Pawl\u0119ga","year":"2013","unstructured":"Pawlikowska-Pawl\u0119ga B, Misiak LE, Zarzyka B, Paduch R, Gawron A, Gruszecki WI. FTIR, 1H NMR and EPR spectroscopy studies on the interaction of flavone apigenin with dipalmitoylphosphatidylcholine liposomes. Biochim Biophys Acta Biomembr. 2013;1828:518\u201327.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"731_CR60","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1016\/j.bmcl.2013.03.018","volume":"23","author":"SR Dennison","year":"2013","unstructured":"Dennison SR, Phoenix DA, Snape TJ. Synthetic oligoureas of metaphenylenediamine mimic host defence peptides in their antimicrobial behaviour. Bioorg Med Chem Lett. 2013;23:2518\u201321.","journal-title":"Bioorg Med Chem Lett"},{"key":"731_CR61","doi-asserted-by":"crossref","unstructured":"Dennison SR, Harris F, Phoenix DA: Langmuir\u2013Blodgett approach to investigate antimicrobial peptide\u2013membrane interactions. Elsevier; 2014.","DOI":"10.1016\/B978-0-12-418698-9.00003-4"},{"key":"731_CR62","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2174\/0929866511009011363","volume":"17","author":"SR Dennison","year":"2010","unstructured":"Dennison SR, Harris F, Phoenix DA. A Langmuir approach using on monolayer interactions to investigate surface active peptides. Protein Pept Lett. 2010;17:1363\u201375.","journal-title":"Protein Pept Lett"},{"key":"731_CR63","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.bbrc.2016.06.054","volume":"477","author":"V Capel","year":"2016","unstructured":"Capel V, Vllasaliu D, Watts P, Stolnik S. Insight into the relationship between the cell culture model, cell trafficking and siRNA silencing efficiency. Biochem Biophys Res Commun. 2016;477:260\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"731_CR64","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/jps.10114","volume":"91","author":"I Pezron","year":"2002","unstructured":"Pezron I, Mitra R, Pal D, Mitra AK. Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (Calu-3). J Pharm Sci. 2002;91:1135\u201346.","journal-title":"J Pharm Sci"},{"key":"731_CR65","first-page":"13","volume-title":"Tous SS","author":"SF Gad","year":"2016","unstructured":"Gad SF, Fetih GN. Tous SS. Pauletti GM: Fabrication of lipid-coated chitosan nanoparticles. Br J Pharmacol Res; 2016. p. 13."},{"key":"731_CR66","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14227\/DT250318P6","volume":"25","author":"A Floroiu","year":"2018","unstructured":"Floroiu A, Klein M, Kr\u00e4mer J, Lehr CM. Towards standardized dissolution techniques for in vitro performance testing of dry powder inhalers. Dissolut Technol. 2018;25:6\u201318.","journal-title":"Dissolut Technol"},{"key":"731_CR67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11095-017-2334-9","volume":"35","author":"S Mangal","year":"2018","unstructured":"Mangal S, Nie H, Xu R, Guo R, Cavallaro A, Zemlyanov D, Zhou QT. Physico-chemical properties, aerosolization and dissolution of co-spray dried azithromycin particles with l-leucine for inhalation. Pharm Res. 2018;35:28.","journal-title":"Pharm Res"},{"key":"731_CR68","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1080\/03639045.2016.1185437","volume":"42","author":"R Kumar","year":"2016","unstructured":"Kumar R, Sinha VR. Solid lipid nanoparticle: an efficient carrier for improved ocular permeation of voriconazole. Drug Deliv Ind Pharm. 2016;42:1956\u201367.","journal-title":"Drug Deliv Ind Pharm"},{"key":"731_CR69","doi-asserted-by":"crossref","unstructured":"Hickey AJ, Mansour HM: Inhalation aerosols: Physical and biological basis for therapy. CRC Press; 2019.","DOI":"10.1201\/9781315159768"},{"key":"731_CR70","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/pharmaceutics11010019","volume":"11","author":"I Aramendia","year":"2019","unstructured":"Aramendia I, Fernandez-Gamiz U, Lopez-Arraiza A, Rey-Santano C, Mielgo V, Basterretxea FJ, Sancho J, Gomez-Solaetxe MA. Experimental evaluation of perfluorocarbon aerosol generation with two novel nebulizer prototypes. Pharmaceutics. 2019;11:19.","journal-title":"Pharmaceutics"},{"key":"731_CR71","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0168-3659(02)00370-X","volume":"86","author":"LA Dailey","year":"2003","unstructured":"Dailey LA, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, Kissel T. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Release. 2003;86:131\u201344.","journal-title":"J Control Release"},{"key":"731_CR72","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1039\/C6CS00636A","volume":"46","author":"S Behzadi","year":"2017","unstructured":"Behzadi S, Serpooshan V, Tao W, Hamaly MA, Alkawareek MY, Dreaden EC, Brown D, Alkilany AM, Farokhzad OC, Mahmoudi M. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev. 2017;46:4218\u201344.","journal-title":"Chem Soc Rev"},{"key":"731_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-016-0238-1","volume":"15","author":"CM da Luz","year":"2017","unstructured":"da Luz CM, Boyles MSP, Falagan-Lotsch P, Pereira MR, Tutumi HR, de Oliveira Santos E, Martins NB, Himly M, Sommer A, Foissner I. Poly-lactic acid nanoparticles (PLA-NP) promote physiological modifications in lung epithelial cells and are internalized by clathrin-coated pits and lipid rafts. J Nanobiotechnology. 2017;15:1\u201318.","journal-title":"J Nanobiotechnology"},{"key":"731_CR74","doi-asserted-by":"publisher","first-page":"17666","DOI":"10.1021\/la303449d","volume":"28","author":"S Nangia","year":"2012","unstructured":"Nangia S, Sureshkumar R. Effects of nanoparticle charge and shape anisotropy on translocation through cell membranes. Langmuir. 2012;28:17666\u201371.","journal-title":"Langmuir"},{"key":"731_CR75","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.tiv.2014.08.003","volume":"29","author":"I George","year":"2015","unstructured":"George I, Vranic S, Boland S, Courtois A, Baeza-Squiban A. Development of an in vitro model of human bronchial epithelial barrier to study nanoparticle translocation. Toxicol In Vitro. 2015;29:51\u20138.","journal-title":"Toxicol In Vitro"},{"key":"731_CR76","first-page":"17","volume":"6","author":"PV Ravikanth","year":"2018","unstructured":"Ravikanth PV, Ramanamurthy KV. Permeability assessment of drug substances using in vitro and ex vivo screening techniques. Innov Pharm Pharmacother. 2018;6:17\u201320.","journal-title":"Innov Pharm Pharmacother"},{"key":"731_CR77","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1128\/AAC.01657-08","volume":"53","author":"JA Tolman","year":"2009","unstructured":"Tolman JA, Wiederhold NP, McConville JT, Najvar LK, Bocanegra R, Peters JI, Coalson JJ, Graybill JR, Patterson TF, Williams RO. Inhaled voriconazole for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2009;53:2613\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"731_CR78","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejpb.2015.02.014","volume":"95","author":"A Hidalgo","year":"2015","unstructured":"Hidalgo A, Cruz A, P\u00e9rez-Gil J. Barrier or carrier? Pulmonary surfactant and drug delivery. Eur J Pharm Biopharm. 2015;95:117\u201327.","journal-title":"Eur J Pharm Biopharm"},{"key":"731_CR79","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4155\/tde-2015-0002","volume":"7","author":"JP Pearson","year":"2016","unstructured":"Pearson JP, Chater PI, Wilcox MD. The properties of the mucus barrier, a unique gel\u2013how can nanoparticles cross it? Ther Deliv. 2016;7:229\u201344.","journal-title":"Ther Deliv"},{"key":"731_CR80","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1152\/physiol.00006.2010","volume":"25","author":"J Perez-Gil","year":"2010","unstructured":"Perez-Gil J, Weaver TE. Pulmonary surfactant pathophysiology: current models and open questions. Physiology. 2010;25:132\u201341.","journal-title":"Physiology"},{"key":"731_CR81","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.bbamem.2011.12.007","volume":"1818","author":"E Keating","year":"2012","unstructured":"Keating E, Zuo YY, Tadayyon SM, Petersen NO, Possmayer F, Veldhuizen RAW. A modified squeeze-out mechanism for generating high surface pressures with pulmonary surfactant. Biochim Biophys Acta Biomembr. 2012;1818:1225\u201334.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"731_CR82","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.bbamem.2008.05.003","volume":"1778","author":"J P\u00e9rez-Gil","year":"2008","unstructured":"P\u00e9rez-Gil J. Structure of pulmonary surfactant membranes and films: the role of proteins and lipid\u2013protein interactions. Biochim Biophys Acta Biomembr. 2008;1778:1676\u201395.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"731_CR83","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejpb.2008.12.014","volume":"72","author":"JA Tolman","year":"2009","unstructured":"Tolman JA, Nelson NA, Son YJ, Bosselmann S, Wiederhold NP, Peters JI, McConville JT, Williams RO. Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. Eur J Pharm Biopharm. 2009;72:199\u2013205.","journal-title":"Eur J Pharm Biopharm"},{"key":"731_CR84","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jconrel.2010.02.006","volume":"144","author":"RR Patlolla","year":"2010","unstructured":"Patlolla RR, Chougule M, Patel AR, Jackson T, Tata P, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Rel. 2010;144:233\u201341.","journal-title":"J Control Rel"},{"key":"731_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-3155-10-20","volume":"10","author":"N Pirooznia","year":"2012","unstructured":"Pirooznia N, Hasannia S, Lotfi AS, Ghanei M. Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles: in vitro characterization as an effective aerosol formulation in pulmonary diseases. J Nanobiotechnology. 2012;10:1\u201315.","journal-title":"J Nanobiotechnology"},{"key":"731_CR86","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/pharmaceutics11080397","volume":"11","author":"PA Makoni","year":"2019","unstructured":"Makoni PA, Wa Kasongo K, Walker RB. Short term stability testing of efavirenz-loaded solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) dispersions. Pharmaceutics. 2019;11:397.","journal-title":"Pharmaceutics"},{"key":"731_CR87","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijpharm.2017.11.024","volume":"536","author":"N Taneja","year":"2018","unstructured":"Taneja N, Singh KK. Rational design of polysorbate 80 stabilized human serum albumin nanoparticles tailored for high drug loading and entrapment of irinotecan. Int J Pharm. 2018;536:82\u201394.","journal-title":"Int J Pharm"},{"key":"731_CR88","doi-asserted-by":"publisher","first-page":"636743","DOI":"10.5402\/2012\/636743","volume":"2012","author":"K Muppidi","year":"2012","unstructured":"Muppidi K, Pumerantz AS, Wang J, Betageri G. Development and stability studies of novel liposomal vancomycin formulations. ISRN Pharmaceutics. 2012;2012:636743.","journal-title":"ISRN Pharmaceutics"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-020-00731-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-020-00731-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-020-00731-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T01:42:15Z","timestamp":1674870135000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-020-00731-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["731"],"URL":"https:\/\/doi.org\/10.1186\/s12951-020-00731-1","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"29 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments are conducted after obtaining ethical approval from the Institutional Animal Ethics Committee of the Panjab University, Chandigarh (PU\/45\/99\/CPSEA\/IAEC\/2019\/243).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No conflicts of interest are declared by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"19"}}